Pricing
  1. JP-listed companies
  2. ReproCELL Incorporated
  3. Financials
  4. Net income margin (%)

ReproCELL Incorporated【JP:4978】

Market cap
¥16B
P/E ratio
-27.8x
Reprocell develops iPS cell technology for research and medical applications, providing lab products and services to pharmaceutical companies while advancing regenerative medicine treatments.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndNet income margin (%) YoY (%)
Mar 31, 20253.5-367.76%
Mar 31, 2024-1.3-87.48%
Mar 31, 2023-10.3-59.83%
Mar 31, 2022-25.7-59.26%
Mar 31, 2021-63.2-25.43%
Mar 31, 2020-84.7+53.33%
Mar 31, 2019-55.3-76.44%
Mar 31, 2018-234.5+223.53%
Mar 31, 2017-72.5-60.59%
Mar 31, 2016-183.9+130.83%
Mar 31, 2015-79.7+207.76%
Mar 31, 2014-25.9-1953.17%
Mar 31, 20131.4-119.91%
Mar 31, 2012-7

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)